Bio-Techne’s RNAScope® Technology Hits 1000 Publications!
Bio-Techne is celebrating an exciting milestone for our RNAScope® assays from the Advanced Cell Diagnostics brand: 1000 publications citing the use of RNAScope® in situ hybridization (ISH) technology! We have announced this milestone in a press release on November 28, 2017.
With 400 of these publications in 2017 alone, this surge includes a notable increase in the use of the RNAScope technology in the pharmaceutical and biotechnology industries. This increase highlights awareness of the robust, sensitive, and specific ISH assay by major players in these industries, including Bayer, Merck, and Eli Lilly.
Dr. Yuling Luo, President and General Manager of Advanced Cell Diagnostics, a Bio-Techne Brand, commented:
"We're very proud of having our customers achieve the 1000-paper milestone so rapidly, with over 900 papers in the last 3 years alone. The fact that RNAscope adoption is expanding into new industries and areas of research, as well as becoming a core assay in biopharmaceutical research and diagnostic development, demonstrates the robustness, sensitivity, and reliability of the assay. It also shows that RNAscope is playing a significant role in advancing numerous research areas and on its way to being a gold standard method in labs."
Three-plex detection of glutaminergic neurons, Vglut1 (Red), Vglut2 (Green), and GABAergic neurons Vgat (white) expression in the FFPE mouse brain with RNAscope® Multiplex Fluorescent Assay v2. Nuclei were labelled with DAPI (Blue)
Read the full press release here.
Learn more about RNAScope Technology